Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 28

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
.Shares of common stock issued and outstandingThree months endedMarch 31,(in millions)20252024Beginning common stock issued and outstanding91.3 89.9 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan0.9 0.6 Common stock issued and outstanding at end of period92.2 90.5 Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:Three months endedMarch 31,(in millions)20252024Denominator:Weighted-average shares outstanding used to compute basic EPS91.4 89.9 Effect of dilutive shares— — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS91.4 89.9 

13

Table of Contents

Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:Three months endedMarch 31,(in millions)20252024Anti-dilutive options and RSUs excluded from EPS computation5.8 6.3 

9.STOCK-BASED COMPENSATION

On November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the "CHCC") of the Board of Directors of the Company, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors. Stockholders have subsequently approved amendments to the 2017 Plan increasing the shares available to grant thereunder, including most recently at the Company's annual meeting of stockholders held on June 1, 2023, when stockholders approved an amendment to the 2017